UNITED THERAPEUTICS Corp
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
UTHR$582.46+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. | Description |
| 3.1 | Restated Certificate of Incorporation of the Registrant, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed October 1, 2021 |
| 3.2 | Eleventh Amended and Restated Bylaws of the Registrant, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed January 22, 2026 |
| 4.1 | Reference is made to Exhibits 3.1 and 3.2 |
| 10.1*+ | Amendment to Exclusive License Agreement, dated as of November 3, 2026 by and between Arena Pharmaceuticals, Inc. and the Registrant |
| 31.1* | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934 |
| 31.2* | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934 |
| 32.1** | Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2** | Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101* | The following financial information from our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 4, 2026, formatted in Inline Extensible Business Reporting Language (iXBRL): (1) our Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025; (2) our Consolidated Statements of Operations for the three- and nine-month periods ended September 30, 2026 and 2025; (3) our Consolidated Statements of Comprehensive Income for the three- and nine-month periods ended September 30, 2026 and 2025; (4) our Consolidated Statements of Stockholders’ Equity for the three- and nine-month periods ended September 30, 2026 and 2025; (5) our Consolidated Statements of Cash Flows for the nine-month periods ended September 30, 2026 and 2025; and (6) the Notes to our Consolidated Financial Statements. |
| 104* | Cover Page Interactive Data File (embedded within the iXBRL document) |
- Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because it is both not material and the type that the Registrant treats as private or confidential.
- Filed herewith.
** Furnished herewith.
Note: Except as otherwise noted above, all exhibits incorporated by reference to the Registrant’s previously filed reports with the Securities and Exchange Commission are filed under File No. 000-26301.
| Quarterly Report | 59 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.